Product Description
Clonidine tablets (Catapres) are used alone or in combination with other medications to treat high blood pressure. Clonidine extended-release (long-acting) tablets (Kapvay) are used alone or in combination with other medications as part of a treatment program to control symptoms of attention deficit hyperactivity disorder (ADHD; more difficulty focusing, controlling actions, and remaining still or quiet than other people who are the same age) in children. Clonidine is in a class of medications called centrally acting alpha-agonist hypotensive agents. Clonidine treats high blood pressure by decreasing your heart rate and relaxing the blood vessels so that blood can flow more easily through the body. Clonidine extended-release tablets may treat ADHD by affecting the part of the brain that controls attention and impulsivity. (Sourced from: https://medlineplus.gov/druginfo/meds/a682243.html)
Mechanisms of Action: ADR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Transdermal
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | Colombia | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Finland | France | Germany | Greece | India | Indonesia | Ireland | Israel | Italy | Korea | Latvia | Lithuania | Luxembourg | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Ukraine | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Hypertension | Hypertension
Known Adverse Events: Dizziness | Headache | Insomnia
Company: Collegium
Company Location: STOUGHTON MA 02072
Company CEO: Joseph Ciaffoni
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China, Egypt, Germany
Active Clinical Trial Count: 5
Highest Development Phases
Phase 3: Attention Deficit Disorder with Hyperactivity|Mucositis|Oropharyngeal Cancer
Phase 2: Stress Disorders, Post-Traumatic
Phase 1: Colorectal Cancer|Pain, Postoperative
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2021-000999-11 | P3 |
Active, not recruiting |
Mucositis|Oropharyngeal Cancer |
2026-02-02 |
|
| ClonDoTrial | P2 |
Active, not recruiting |
Stress Disorders, Post-Traumatic |
2024-12-20 |
|
| ClonDoTrial | P2 |
Recruiting |
Stress Disorders, Post-Traumatic |
2024-07-31 |
|
| Nirvana Ahmed | P1 |
Completed |
Colorectal Cancer|Pain, Postoperative |
2022-01-01 |
44% |
| Nirvana Ahmed | P1 |
Completed |
Colorectal Cancer|Pain, Postoperative |
2022-01-01 |
44% |